Imperial Recognized as 2026 National Best and Brightest Company to Work For! Learn More

Imperial Clinical Research Services Blog
  • Services
    • What We Do
    • Study and Site Print Materials
    • Clinical Trial Translation Management
    • Ancillary Trial Supplies and Equipment
    • Clinical Trial Patient Engagement
    • CRO-Centered Services
    • A La Carte Services
  • Resources
    • Ebooks
    • Case Studies & Fact Sheets
  • About
    • About Us
    • News
    • Events
    • Corporate Responsibility
  • Contact
    • Contact Imperial
    • Career Opportunities
  • Blog
  • Marketplace
  • Services
    • What We Do
    • Study and Site Print Materials
    • Clinical Trial Translation Management
    • Ancillary Trial Supplies and Equipment
    • Clinical Trial Patient Engagement
    • CRO-Centered Services
    • A La Carte Services
  • Resources
    • Ebooks
    • Case Studies & Fact Sheets
  • About
    • About Us
    • News
    • Events
    • Corporate Responsibility
  • Contact
    • Contact Imperial
    • Career Opportunities
  • Blog
  • Marketplace
Ancillary Clinical Trial Supplies and Equipment Clinical Trial Business Insights

Beyond Logistics: Clinical Trial Supply & Equipment Risk Management

by Kristi Killman November 10, 2026
Ancillary Clinical Trial Supplies and Equipment Clinical Trial Materials Development and Printing

Clinical Trial Startup Challenges: What’s Lurking Around the Corner?

by Dan McDonald October 29, 2026
Clinical Trial Business Insights

The Rhythm of a Year

by Brandon Bissell October 27, 2026
Ancillary Clinical Trial Supplies and Equipment Clinical Trial Business Insights

GCSG European Knowledge Forum: More Than Just Another Conference

by Imogen Cheese October 22, 2026
Ancillary Clinical Trial Supplies and Equipment

Building Flexibility Into Clinical Trial Equipment Planning

by Ted Corrigan October 6, 2026
Clinical Trial Materials Development and Printing Participant Engagement

Just-in-Time Printing for Clinical Trials: A Smarter Approach

by Karlton Gray September 21, 2026
Clinical Trial Materials Development and Printing Participant Engagement Translation of Clinical Trial Materials

3 Steps to Create User-Friendly Participant Materials

by Marta Korgol September 9, 2026
Clinical Trial Business Insights

Rethinking Diversity Through Inclusive Clinical Trial Design

by Vaughn X. Anthony September 2, 2026
Clinical Trial Business Insights Clinical Trial Materials Development and Printing Translation of Clinical Trial Materials

How Version Control in Clinical Trial Materials Reduces Risk

by Heather Ross August 26, 2026
Ancillary Clinical Trial Supplies and Equipment

Why Ancillary Supplies Are Rarely Ancillary in Clinical Trials

by Imogen Cheese August 4, 2026
  • Study & Site Print Materials

  • Ancillary Trial Supplies

  • Translation Services

  • Trial Patient Engagement

    Clinical Trial Materials Development and Printing

    Writing Clinical Study Materials: Why Starting Early Can Be an Option

    by Liz Wegner May 6, 2026
    written by Liz Wegner
    Clinical trial professionals with a study calendar being crossed off and a laptop being used to write research materials

    Clinical studies follow established timelines, and the work of preparing site and participant materials typically begins at a predictable point in that process. Most study teams assume writing begins only after the protocol is approved, and often don’t consider alternatives.

    Naturally, the best time to write site and participant study materials is after the protocol is finalized. A final protocol is a reliable confirmed source: visit schedules, assessments, procedures, and language will not change without an amendment. Ideally, teams would always wait for this level of stability before writing.

    But there are situations where beginning the writing process early can be considered, especially when the protocol is moving through an extended period of internal review, scientific and medical governance review, operational refinements, and final quality checks.

    Is Now a Good Time to Start Writing?

    Early writing becomes appropriate when the research protocol is stable enough that its core structure is unlikely to change. Once the visit schedule, major assessments, and overall study flow are reasonably established, teams can begin shaping the research materials with the understanding that the content will be reviewed and updated where necessary later.

    Getting started early with your digital and print materials helps in two key ways that directly affect timelines and workload:

    Momentum

    When the protocol is finalized, instead of starting from scratch with a blank page, you’re well into the writing process and closer to the finish line.

    Visibility

    Early writing is an opportunity to assess formats and word‑count realities and make decisions early. For example, a trifold brochure may need to become a four‑panel piece or even a booklet once you see the level of detail that’s required. Or you might decide it will be more user-friendly to create separate visit guides for the main study and the extension study. This phase also gives designers enough information to begin shaping concepts, and placing draft text into early layouts helps reveal how content will fit and flow.

    Practical Tips for Working From a Draft Clinical Trial Protocol

    These tips can help keep your drafts accurate while the protocol is still evolving:

    • Indicate the source on every document. Add a simple line at the top of each document, such as “Written from protocol version dated [YYYY/MM/DD].” This makes it clear that the content is not final and that it needs to be checked and updated.
    • Expect reviewers to work ahead of the protocol. It’s common for reviewers to incorporate changes they know are coming, such as an added visit, an extra blood draw, or a new assessment, even if those updates aren’t yet reflected in the draft protocol. This is why early drafts sometimes contain a mix of protocol language and assumptions, and why each document will need to be checked in its entirety later.

    Once the Protocol Is Final

    Once the protocol is approved, your materials need to be brought into full alignment. Treating this as a fresh and full review, not a quick patch, ensures your documents accurately reflect the study.

    It is important to review every word of every piece, even the simplest items like thank-you cards and appointment cards, to verify their accuracy. And even if you know that the only change between the draft and the final is, say, one more blood draw at Visit 6, resist the temptation to make that single update and call it done. Check everything.

    Why Writing Clinical Study Materials From Early Protocol Versions Works

    Early writing can help reduce the crush of work that follows protocol approval and give teams the clarity they need to make early decisions about format, flow, and workload.

    When handled with a thorough check after the protocol is approved, early writing becomes one of the simplest ways to keep study materials accurate, aligned, and on schedule.

    Writing without an approved protocol is not the ideal way to work, and we don’t recommend it as a standard process. But early writing can be effective when it’s supported by clear version control and a disciplined reconciliation process. With the right checks in place once the protocol is approved, teams can use early drafts to maintain momentum without compromising accuracy.

    How Imperial Supports Early Writing

    Imperial’s writers, editors, and designers work directly from draft protocols when early writing makes sense and the protocol structure is reasonably stable. When the approved protocol arrives, we perform a full reconciliation across every piece to ensure accuracy before materials move into production.

    This disciplined approach can help meet timelines and give study teams confidence that all participant and site materials reflect the final approved protocol.

    If your protocol is still moving through reviews, it may be a good time for Imperial to begin shaping your materials so you’re not starting from zero when the final version arrives. We’re happy to discuss your timeline and determine whether early writing is appropriate for your study.

    Quick Q&A: Common Questions About Early Writing

        1. Can study materials be written before the protocol is finalized?

    Yes. While the ideal time to write is after approval, early writing can be considered when the protocol’s core structure is stable and the review period is lengthy. The key is understanding that all early drafts will require a full reconciliation once the final protocol arrives.

        2. What parts of the protocol need to be stable before early writing begins?

    The visit schedule, major assessments, and overall study flow should be reasonably established. These elements shape both digital and print materials, so they need to be far enough along that major structural changes are unlikely.

        3. What are the advantages of starting early?

    Early writing helps teams maintain momentum and reduces the volume of work that typically accumulates after protocol approval. It also provides early visibility into format, layout, and word-count needs. This is especially helpful for print pieces that require specific space and design considerations.

        4. How do teams ensure accuracy if they start from a draft protocol?

    Accuracy comes from disciplined version control and a full, line‑by‑line reconciliation once the protocol is approved. Every piece, no matter how simple, should be reviewed against the final protocol to ensure all details match.

     

    Sign Up For Imperial Blog Alerts
    Contact Us
    May 6, 2026 0 comments
    1 FacebookTwitterLinkedinEmail
  • Clinical Trial Materials Development and PrintingParticipant Engagement

    The Reader Experience: Making Clinical Research Participant Materials Easy to Use

    by William McEwen April 22, 2026
    by William McEwen April 22, 2026

    Much of life is rooted in communication, and this is certainly true in clinical research. Every study interaction, whether in person or through participant clinical trial materials, depends on clear and reliable information. When we communicate with participants, we convey essential details and set expectations. …

    1 FacebookTwitterLinkedinEmail
  • Clinical Trial Business Insights

    Risk Management in Clinical Trials Through Effective CAPA Practice

    by Frances Bentley April 8, 2026
    by Frances Bentley April 8, 2026

    Risk management in clinical trials depends on systems that detect issues, correct them, and prevent them from returning. Corrective and Preventive Actions (CAPAs) are the structured process used to investigate deviations, address root causes, and strengthen controls. When CAPAs work, they protect study integrity and …

    0 FacebookTwitterLinkedinEmail
  • Clinical Trial Business Insights

    Sustainability in Action: ESG and Clinical Research

    by Dan McDonald March 16, 2026
    by Dan McDonald March 16, 2026

    Sustainability has become a top priority for businesses and now shapes how they are evaluated and trusted. Companies in every industry are judged not only on their results and profits, but also on how they operate. In life sciences, using sustainable practices in clinical trials …

    0 FacebookTwitterLinkedinEmail
  • Clinical Trial Business InsightsParticipant Engagement

    Harnessing Collective Intelligence in Clinical Trials

    by Hope Cullen March 10, 2026
    by Hope Cullen March 10, 2026

    Clinical studies are complex, and they work better when the people involved share what they know. That may sound obvious, but sponsors, CROs, sites, technology partners, and patients often end up working in separate corners. This makes it harder for important information to move where …

    0 FacebookTwitterLinkedinEmail
Load More Posts

Signup for our Blog Subscription

Signup for our Blog Subscription

Keep in touch

Twitter Linkedin Youtube Email Rss

Popular Posts

  • 1

    Clinical Research Phases and the Path to Drug Approval

    August 8, 2023
  • 2

    See Do Get

    August 12, 2014
  • 3

    Google Translate: The Unwitting Confidentiality Flaw

    April 15, 2020
  • 4

    25 Reasons People Aren’t Enrolling in Your Clinical Trial

    October 29, 2015
  • 5

    The Upcoming FDA Clinical Trial Diversity Mandate: What You Need to Know

    May 14, 2025

Categories

  • Ancillary Clinical Trial Supplies and Equipment (44)
  • Clinical Trial Business Insights (198)
  • Clinical Trial Materials Development and Printing (55)
  • Participant Engagement (113)
  • Translation of Clinical Trial Materials (21)
Imperial Clinical Research Services Blog

Imperial is a global leader in clinical trial solutions and support, specializing in study and site print materials, ancillary trial supplies and equipment, clinical trial translation management, and clinical trial patient engagement.

Imperial CRS Corporate Headquarters
3100 Walkent Drive NW
Grand Rapids, MI 49544

Contact

connect@imperialcrs.com

800.777.2591

020 3887 3437

Employment

Social

We Run on EOS - Entrepreneurial Operating SystemEcovadis Sustainability Rating January 2024West Michigan's Best and Brightest Companies to Work For Winner 2025The Best and Brightest Companies to Work For Logo
© Imperial CRS, LLC | Privacy Policy
Signup for our Blog Subscription

Subscribetoourblogandgetthelatestupdates,insights,andindustrytrendsdeliveredstraighttoyourinbox.Stayinformedandnevermissapost.

 

 


Imperial Clinical Research Services Blog
  • Services
    • What We Do
    • Study and Site Print Materials
    • Clinical Trial Translation Management
    • Ancillary Trial Supplies and Equipment
    • Clinical Trial Patient Engagement
    • CRO-Centered Services
    • A La Carte Services
  • Resources
    • Ebooks
    • Case Studies & Fact Sheets
  • About
    • About Us
    • News
    • Events
    • Corporate Responsibility
  • Contact
    • Contact Imperial
    • Career Opportunities
  • Blog
  • Marketplace